false 0001625101 0001625101 2023-09-10 2023-09-10

 

 

 

 

Date of Report (Date of Earliest Event Reported): September 10, 2023

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

On September 10, 2023, the Board of Directors of Pulse Biosciences Inc., a Delaware corporation (the “Company”), upon the recommendation of its Compensation Committee, approved one-time cash bonuses, each in the amount of $300,000, payable to Mr. Kevin Danahy, the Company’s President and Chief Executive Officer, and to Mr. Darrin Uecker, its Chief Technology Officer, for their leadership and the Company’s programmatic achievements in 2023. The parties have agreed that each of these bonuses will be credited against any future bonuses otherwise payable to Messrs. Danahy and Uecker, pursuant to the Company’s 2023 bonus plan and their employment agreements with the Company.

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.